AbbVie
The effort will be focused on using nocturnal scratch as an endpoint for atopic dermatitis.
HIMSS21
Chris Boone, global head of health economics and outcomes research at AbbVie, shares why pharmaceutical companies are still working to improve diversity in clinical trials.
Pharma companies also continued to explore the promises of digital therapeutics.
The pair plans to use MC10's FDA-cleared wearable sensors, called BioStamp nPoint, to get insights into a patient's physiological data during the studies.